Extended Erythropoietin Treatment Prevents Chronic Executive Functional and Microstructural Deficits Following Early...

Area of Science:

• Neuroscience
• Developmental Neuroscience
• Regenerative Medicine

Background:

• Infant traumatic brain injury (TBI) survivors often experience lifelong neurological deficits.
• Translating TBI interventions to clinical trials is challenging due to a lack of representative preclinical models and outcome biomarkers.

Purpose of the Study:

• To evaluate the efficacy of an extended, high-dose erythropoietin (EPO) regimen in preventing chronic cognitive and imaging deficits in a preclinical model of infant TBI.

Main Methods:

• A controlled cortical impact (CCI) model was used on postnatal day 12 rats.
• Cognitive function was assessed using touchscreen operant chambers.
• Brain microstructural integrity was analyzed using diffusion tensor imaging (DTI) at subacute (P30) and chronic (P90) time points.

Main Results:

• EPO treatment prevented widespread microstructural brain damage observed at P30.
• CCI rats receiving vehicle failed to improve in reversal learning tasks, unlike EPO-treated rats.
• Chronic DTI at P90 revealed EPO prevented white matter and prefrontal cortex damage, correlating with cognitive improvements.

Conclusions:

• Extended EPO treatment effectively restores executive function and prevents brain abnormalities in a preclinical model of infant TBI.
• Advanced preclinical testing methods, including touchscreen operant chambers and DTI, can accelerate the translation of TBI interventions.
• These findings support the investigation of EPO in clinical trials for human infants with TBI.